Seattle Genetics (SGEN) 'Buy' Reiterated at Jefferies After Q1 Results and Ahead of Pipeline News
Tweet Send to a Friend
Jefferies analyst Thomas Wei reiterated a Buy rating and $53 price target on Seattle Genetics (NASDAQ: SGEN) following Q1 results ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE